JP2023543262A - イヌ科動物抗体バリアント - Google Patents

イヌ科動物抗体バリアント Download PDF

Info

Publication number
JP2023543262A
JP2023543262A JP2023519180A JP2023519180A JP2023543262A JP 2023543262 A JP2023543262 A JP 2023543262A JP 2023519180 A JP2023519180 A JP 2023519180A JP 2023519180 A JP2023519180 A JP 2023519180A JP 2023543262 A JP2023543262 A JP 2023543262A
Authority
JP
Japan
Prior art keywords
igg
antibody
constant domain
canine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543262A5 (enExample
Inventor
バージェロン，リサ・マリー
カンポス，ヘンリー・ルイス
Original Assignee
ゾエティス・サービシーズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾエティス・サービシーズ・エルエルシー filed Critical ゾエティス・サービシーズ・エルエルシー
Publication of JP2023543262A publication Critical patent/JP2023543262A/ja
Publication of JP2023543262A5 publication Critical patent/JP2023543262A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023519180A 2020-09-28 2021-09-28 イヌ科動物抗体バリアント Pending JP2023543262A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28
US63/084,241 2020-09-28
PCT/US2021/052338 WO2022067233A2 (en) 2020-09-28 2021-09-28 Canine antibody variants

Publications (2)

Publication Number Publication Date
JP2023543262A true JP2023543262A (ja) 2023-10-13
JP2023543262A5 JP2023543262A5 (enExample) 2024-09-27

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519180A Pending JP2023543262A (ja) 2020-09-28 2021-09-28 イヌ科動物抗体バリアント

Country Status (17)

Country Link
US (1) US12612454B2 (enExample)
EP (1) EP4217384A2 (enExample)
JP (1) JP2023543262A (enExample)
KR (1) KR20230079148A (enExample)
CN (1) CN116438196A (enExample)
AR (1) AR123636A1 (enExample)
AU (1) AU2021349301A1 (enExample)
BR (1) BR112023005393A2 (enExample)
CA (1) CA3194936A1 (enExample)
CL (2) CL2023000878A1 (enExample)
CO (1) CO2023004102A2 (enExample)
EC (1) ECSP23030271A (enExample)
IL (1) IL301413A (enExample)
MX (1) MX2023003624A (enExample)
PE (1) PE20231374A1 (enExample)
TW (1) TW202229337A (enExample)
WO (1) WO2022067233A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
MX2023003624A (es) 2020-09-28 2023-04-11 Zoetis Services Llc Variantes de anticuerpos caninos.
AU2023289332A1 (en) * 2022-06-21 2024-12-12 Zoetis Services Llc Canine antibody mutants
JP2026508096A (ja) 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
US20200216536A1 (en) * 2019-01-03 2020-07-09 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
EP3887397A1 (en) * 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP7536294B2 (ja) * 2018-12-05 2024-08-20 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
CN115996949A (zh) 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
MX2023003624A (es) 2020-09-28 2023-04-11 Zoetis Services Llc Variantes de anticuerpos caninos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
US20200216536A1 (en) * 2019-01-03 2020-07-09 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Also Published As

Publication number Publication date
CL2024000628A1 (es) 2024-07-19
TW202229337A (zh) 2022-08-01
CL2023000878A1 (es) 2023-10-20
KR20230079148A (ko) 2023-06-05
EP4217384A2 (en) 2023-08-02
AU2021349301A1 (en) 2023-08-24
US20240010716A1 (en) 2024-01-11
CA3194936A1 (en) 2022-03-31
CN116438196A (zh) 2023-07-14
WO2022067233A3 (en) 2022-05-27
WO2022067233A2 (en) 2022-03-31
CO2023004102A2 (es) 2023-04-05
AR123636A1 (es) 2022-12-28
MX2023003624A (es) 2023-04-11
BR112023005393A2 (pt) 2023-04-25
IL301413A (en) 2023-05-01
US12612454B2 (en) 2026-04-28
PE20231374A1 (es) 2023-09-07
ECSP23030271A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
US20230242635A1 (en) Canine antibody variants
US20250026834A1 (en) Feline antibody variants
US12612454B2 (en) Canine antibody variants
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
JP2023551194A (ja) ウシ科動物抗体バリアント
TWI880316B (zh) 貓抗體變異體
RU2840969C1 (ru) Варианты кошачьих антител
JP2025524441A (ja) イヌ科動物抗体変異体
HK40121344A (en) Mutations in canine antibody constant regions
JP2025525987A (ja) ウシ亜科動物抗体変異体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260415